24 January 2019
\n \n \n \nThe Department of Oncology is pleased to announce that Professor Amato J Giaccia has been appointed as the new Director of the MRC Oxford Institute for Radiation Oncology (OIRO).
\n \n\n \n \n30 November 2018
\n \n \n \nResearchers in the Department of Oncology have secured funding to characterise an insulin-like growth factor (IGF) signature for early detection and risk reduction of cancer.
\n \n\n \n \n26 November 2018
\n \n \n \nScientists from the Department of Oncology have equipped a virus that kills carcinoma cells with a protein so it can also target and kill adjacent cells that are tricked into shielding the cancer from the immune system.
\n \n\n \n \n6 November 2018
\n \n \n \nGreg Clark, UK Secretary of State for Business, Energy and Industrial Strategy (BEIS), will confirm today (Tuesday 6 November) that UK Research and Innovation will invest \u00a310million in the National Consortium of Intelligent Medical Imaging (NCIMI), to be led from Oxford University as part of the Industrial Strategy Challenge Fund.
\n \n\n \n \n28 September 2018
\n \n \n \nCongratulations to Dr Serena Lucotti, who has been awarded 'Italy Made Me' prize for her DPhil project.
\n \n\n \n \n12 July 2018
\n \n \n \nThe 6th Annual Oncology Student Symposium was held at St Anne\u2019s College, for the second time, on Monday, 9 July.
\n \n\n \n \n10 April 2018
\n \n \n \nCongratulations to Dr Xiao Wan from Professor Eric O\u2019Neill\u2019s group for her success in obtaining an NC3Rs Training Fellowship for \u2018Developing human organotypic perfused bioreactors for physiologically reproducible therapeutic compound screening of a tumour microenvironment\u2019.
\n \n\n \n \n6 April 2018
\n \n \n \nCongratulations to Dr Bart Cornelissen of the CRUK/MRC Oxford Institute for Radiation Oncology, Department of Oncology who has secured a \u00a3200k grant from UK medical research charity, Pancreatic Cancer Research Fund (PCRF).
\n \n\n \n \n3 April 2018
\n \n \n \nDr James Larkin, a postdoctoral researcher from Nicola Sibson\u2019s lab in the CRUK/MRC Oxford Institute for Radiation Biology, has won a silver medal in 2018 STEM for Britain, a Parliamentary poster competition that gives researchers the chance to present their work to policymakers and politicians and discuss their work with local MPs.
\n \n\n \n \n22 January 2018
\n \n \n \nMany congratulations to Robert Watson, a NIHR Academic Clinical Fellow in the laboratory of Benjamin Fairfax in the Department of Oncology. Robert was successful in his application for a CRUK pre-doctoral research bursary.
\n \n\n \n \n8 December 2017
\n \n \n \nCongratulations to Associate Professor Francesca Buffa who has been awarded a five-year \u20ac2M grant by the European Research Council (ERC) to develop computer simulations of cancer cell behaviour, to help us personalise cancer treatment and prevent drug resistance.
\n \n\n \n \n28 November 2017
\n \n \n \nThis month the MRC Weatherall Institute of Molecular Medicine (WIMM) hosted the annual Regional Breast Cancer Academic Day, an event that brings together breast cancer teams from across the Thames Valley region. This year\u2019s symposium involved the participation of over 70 attendees, including nurses, clinical trial managers, researchers and doctors.
\n \n\n \n \n13 October 2017
\n \n \n \nProfessor Nicola Sibson of the Department of Oncology has been awarded a grant worth almost \u00a3200,000 by research charity Breast Cancer Now to fund cutting-edge research to uncover novel treatment combinations to control breast cancer that has spread to the brain.
\n \n\n \n \n3 October 2017
\n \n \n \nA new study carried out by the University of Oxford has used flat worms to look at the role of migrating stem cells in cancer.
\n \n\n \n \n30 June 2017
\n \n \n \nToday a new drug will become available for patients with bowel cancer as part of a national clinical trial; based on a scientific discovery made only two years ago at the University of Oxford.
\n \n\n \n \n27 March 2017
\n \n \n \nThe development of new treatments for pancreatic cancer is set to be transformed by a network of pancreatic clinical trials, aiming to find the right trial for the right patient, after a \u00a310 million investment from Cancer Research UK announced today.
\n \n\n \n \n13 February 2017
\n \n \n \nUsing funding from CRUK and Psioxus Therapeutics, a team of researchers from the University of Oxford led by Professor Len Seymour, have recently published a paper in Molecular Therapy Oncolytics.
\n \n\n \n \n